Xeris Biopharma HoldingsXERS
XERS
About: Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
Employees: 377
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
271% more call options, than puts
Call options by funds: $1.26M | Put options by funds: $340K
79% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 14
31% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 35
30% more capital invested
Capital invested by funds: $141M [Q2] → $183M (+$42.4M) [Q3]
6% more funds holding
Funds holding: 134 [Q2] → 142 (+8) [Q3]
0.92% more ownership
Funds ownership: 42.24% [Q2] → 43.16% (+0.92%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$3
9%
downside
Avg. target
$4.80
45%
upside
High target
$6.60
100%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
HC Wainwright & Co. Oren Livnat 46% 1-year accuracy 21 / 46 met price target | 100%upside $6.60 | Buy Maintained | 11 Nov 2024 |
Piper Sandler David Amsellem 58% 1-year accuracy 23 / 40 met price target | 9%downside $3 | Neutral Downgraded | 11 Nov 2024 |
Financial journalist opinion
Based on 3 articles about XERS published over the past 30 days
Neutral
PRNewsWire
1 day ago
The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness
Strategic collaboration formed to raise awareness that all people with diabetes on blood glucose-lowering medications should have glucagon, preferable a ready-to-use formulation CHICAGO and ARLINGTON, Va. , Jan. 21, 2025 /PRNewswire/ -- The American Diabetes Association® (ADA) and Xeris Pharmaceuticals® (Xeris BioPharma Holdings, Inc.), a national supporter of the ADA, are pleased to announce a multi-year strategic partnership to reinforce the importance of prescribing glucagon, preferably ready-to-use, for all individuals with diabetes who are treated with insulin and/or insulin secretagogues or those at high risk of hypoglycemia (low blood glucose, also called low blood sugar), in line with the ADA's recently updated Standards of Care in Diabetes—2025 (Standards of Care).1 "Severe hypoglycemia is life-threatening, and people with diabetes on blood glucose-lowering medication are at risk for hypoglycemia.
Neutral
Business Wire
1 week ago
Xeris Expects to Exceed Full-Year 2024 Financial Guidance
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced it expects to generate total 2024 revenue of $203 million, which will exceed previously announced 2024 total revenue guidance of $198 million to $202 million. The Company also anticipates ending 2024 with over $71 million in cash, cash equivalents, and short-term investments, generating positive cash flow in the fourth quarter. “We achieved another record quarter of exceptional total revenue growth with reve.
Neutral
Business Wire
2 weeks ago
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on January 2, 2025, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 181,500 shares of its common stock to 19 new employee(s) under Xeris' Inducement Equity Plan. Xeris' Inducement Eq.
Neutral
Business Wire
1 month ago
Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 at 8:00am Eastern Time. A live webcast of the event will be available on the 'Events &.
Neutral
Seeking Alpha
2 months ago
Xeris Biopharma Holdings, Inc. (XERS) Q3 2024 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants John Shannon - Chief Executive Officer Steve Pieper - Chief Financial Officer Allison Wey - Senior Vice President of Investor Relations, Corporate Communications Conference Call Participants Chase Knickerbocker - Craig-Hallam Leland Gershell - Oppenheimer. Oren Livnat - HC Wainwright Nik Gasic - Leerink Partners David Amsellem - Piper Sandler Operator Hello and welcome to the Xeris Biopharma Third Quarter 2024 Financial Results Conference Call.
Neutral
Zacks Investment Research
2 months ago
Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Xeris Biopharma (XERS) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Negative
Zacks Investment Research
2 months ago
Xeris Biopharma (XERS) Reports Q3 Loss, Tops Revenue Estimates
Xeris Biopharma (XERS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.09 per share a year ago.
Neutral
Business Wire
2 months ago
Xeris Biopharma Reports Third Quarter 2024 Financial Results
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter and nine months ended September 30, 2024. “We are proud to report our record-breaking quarter with total revenue of our $54 million led by strong demand of Recorlev® and Gvoke®. Our product revenue growth of 2.
Neutral
Business Wire
2 months ago
Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its third quarter 2024 financial results before the open of the U.S. financial markets on Friday, November 8, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss t.
Positive
Seeking Alpha
2 months ago
Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive
Xeris Biopharma Holdings, Inc. is an overlooked specialty pharmaceutical company with three FDA-approved products, utilizing its proprietary XeriSol and XeriJect technologies to develop innovative injectable drug formulations. Gvoke and Recorlev drive Xeris' rapid growth, with Gvoke holding 34% of the retail glucagon market and Recorlev expanding its patient base by 124%. Xeris' strategic partnerships and promising pipeline, particularly XP-8121 for hypothyroidism, offer strong potential for value creation and long-term growth.
Charts implemented using Lightweight Charts™